The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. …"

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Mean Scores in 11-step anxiety in UK, 2012–2021 (weighted), 2011–2021. حسب David G. Blanchflower (8011427)

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"

Expression of lipid biosynthetic genes is decreased with polyamine depletion. حسب Yazmin E. Cruz-Pulido (20285238)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

Table of step height. حسب Jianbo Jia (717814)

الموضوعات:

The well wall step. حسب Jianbo Jia (717814)

الموضوعات:

LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... حسب Mouad Klai (20818364)

Frequencies of IgM⁺ B cells, myeloid cells and CD8⁺ T cells of control and exposed brown trout in Wild, Wild:Farm and Farm groups. حسب Helena Saura Martinez (22305113)

الموضوعات:

qPCR results of <i>T. bryosalmonae</i> DNA amplification on brown trout kidney and estimated concentration. حسب Helena Saura Martinez (22305113)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات: